India Announces Major Price Reductions for Selected Cancer Medicines

The cost of cancer treatment remains a major concern for patients and families, particularly when treatment involves repeated hospital visits, specialised medicines, diagnostic tests, and supportive care.

On 29 October 2026, The Indian Express reported reductions in the prices of selected cancer medicines following changes to medicine pricing and trade margins.

The report highlighted thiotepa, a chemotherapy medicine used in certain cancer treatment settings. Its reported price for a 100 mg vial decreased from ₹80,071 to ₹7,150. Pertuzumab, a targeted medicine used in specific breast cancer treatment settings, was also reported to have a substantial price reduction, from ₹94,951 to ₹30,593 for a 30 mg vial. The Indian Express

These reductions could be significant for patients whose treatment plans include the affected products. However, they should not be interpreted as a reduction in the cost of every cancer medicine or every cancer treatment.

Cancer treatment is highly individualised. The medicines prescribed depend on the cancer type, stage, tumour characteristics, previous treatment, and the patient's general health. Some patients may require surgery, radiation therapy, chemotherapy, immunotherapy, targeted medicines, or combinations of these approaches.

Lower medicine prices can help address one part of the financial burden, but patients may still face expenses for hospitalisation, investigations, specialist consultations, and supportive care.

Patients and caregivers should confirm the applicable price, formulation, and availability with a licensed pharmacy or treating hospital. Prescribed cancer medicines should not be substituted or discontinued without the oncologist's guidance.

The development highlights the importance of balancing affordable treatment with reliable medicine supplies, quality standards, and access to appropriate cancer care.